ストックスクリーナーアプリを入手
18.04
4.28%
0.74
アフターアワーズ：
18.07
0.03
+0.17%
前日終値:
$17.30
開ける：
$18.54
24時間の取引高:
554.69K
Relative Volume:
1.36
時価総額：
$2.09B
収益：
$7.50M
当期純損益:
$-81.89M
株価収益率:
0.3403
EPS:
53.0176
ネットキャッシュフロー:
$-63.58M
1週間 パフォーマンス:
+6.24%
1か月 パフォーマンス:
+23.31%
6か月 パフォーマンス:
+149.52%
1年 パフォーマンス:
+839.58%
1日の値動き範囲:
$17.82
$18.93
1週間の範囲:
$15.92
$18.93
52週間の値動き範囲:
$1.7201
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
18.04 | 2.09B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-23 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-24 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-29 | アップグレード | Jefferies | Hold → Buy |
| 2024-07-23 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-07 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 開始されました | William Blair | Outperform |
| 2022-12-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-09-06 | 開始されました | Piper Sandler | Overweight |
| 2021-04-07 | アップグレード | Maxim Group | Hold → Buy |
| 2020-12-22 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-12-04 | ダウングレード | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2020-05-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-31 | 再開されました | H.C. Wainwright | Buy |
| 2018-03-22 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-08-31 | 開始されました | Oppenheimer | Outperform |
| 2017-06-08 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Mesoblast Ltd Adr (MESO) 最新ニュース
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Investors: What’s The Real Deal With W & T Offshore Inc (NYSE: WTI) - Stocks Register
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
No Stopping Argo Blockchain Plc ADR (NASDAQ: ARBK)’s Stock Plunged? - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
What Do Analysts Think About Aspen Aerogels Inc’s (NYSE:ASPN) Future? - Stocks Register
Would I Buy Opendoor Technologies Inc (NASDAQ: OPEN) Stock At Any Time In The Future? - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Petco Health and Wellness Co Inc (NASDAQ: WOOF): A Hidden Gem Despite Volatility - Stocks Register
Where Do Analysts See Gamestop Corporation (NYSE: GME) Heading? - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology - Benzinga
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Best Momentum Stocks to Buy for November 26th - Yahoo Finance
Investors Heavily Search Sea Limited Sponsored ADR (SE): Here is What You Need to Know - Yahoo Finance
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
Mesoblast files annual report and meeting notice - Investing.com India
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast stock soars to 52-week high, hits $8.7 - Investing.com
What Makes Holcim Ltd Unsponsored ADR (HCMLY) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Mesoblast stock gains momentum ahead of 2025 PDUFA dateJefferies - Investing.com
The Psychology of Mesoblast Ltd ADR Inc. (MESO) Price Performance: Understanding Market Sentiment - The InvestChronicle
Why Argosy Minerals, Flight Centre, Mesoblast, and Telix shares are sinking today - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 0.50% - Investing.com
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.81% - Investing.com
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.99% - Investing.com
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
11 Best ASX Stocks To Buy Now - Yahoo Finance
Sea Limited (SE) to Report Q4 Earnings: What's in Store? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Top Penny Stocks for Q3 2023 - Investopedia
Here’s why Mesoblast shares are in a trading halt today - The Motley Fool Australia
Class action proposed against biotech Mesoblast after historic collapse in share price - Business News Australia
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Exclusive Interview With Pluristem Therapeutics Inc.(NASDAQ:PSTI) President Yaky Yanay - Market Exclusive
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) On Track to Becoming Largest Generics Manufacturer - The Wall Street Transcript
Mesoblast Ltd Adr (MESO) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):